John Albin is an Infectious Disease physician affiliated with Harvard University. OpenAlex indexes 46 publications with 1,069 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit Street
Gray-Jackson 504
Boston, MA 02114
Telephone
617-726-3812Registry record last updated 30 Apr 2019.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Mannkind CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
62.1%Macrolide Antimicrobial62.1%Azithromycin100%Part D≥41 patientsAntiparasitic
37.9%Antimalarial37.9%Atovaquone-Proguanil Hcl100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Protein engineering for the development of novel antimicrobial agents
Massachusetts General Hospital
FY2026$196,560K08AI166345 - Protein engineering for the development of novel antimicrobial agents
Massachusetts General Hospital
FY2025$196,560K08AI166345 - Protein engineering for the development of novel antimicrobial agents
Massachusetts General Hospital
FY2025$35,238K08AI166345
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Modulation of the human cathelicidin dimerization interface separates antimicrobial activity from mammalian membrane disruption
bioRxiv (Cold Spring Harbor Laboratory)
2026 - A portable N-terminal biphenyl motif in LL-37 enhances the activity of short human cathelicidin derivatives
bioRxiv (Cold Spring Harbor Laboratory)
2025 - Bedaquiline for the Treatment of Pulmonary Non-tuberculous Mycobacterial Infections: Retrospective Analysis From a Large Healthcare System
American Journal of Respiratory and Critical Care Medicine
2025 - Decoupling membrane permeabilization and antimicrobial activity in amphipathic peptides
bioRxiv (Cold Spring Harbor Laboratory)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”